Description and analysis of differential sensitivity to glucocorticoids in Fao cells.
This study shows that the derived hepatoma cell line Fao displays different sensitivities for glucocorticoid induction of tyrosine aminotransferase (TAT), alanine aminotransferase (AAT) and gamma-glutamyltransferase (GGT). This was seen in the different behaviors of nine steroids with respect to these three effects: (1) in the presence of full agonists (dexamethasone or deacylcortivazol), half-maximal induction of GGT occurred at approx 5- to 6-fold higher agonist concentrations than those required for half-maximal induction of AAT and TAT; (2) in the presence of full antagonists (RU 486, R5020, or progesterone) the GGT response induced by an equal agonist concentration was inhibited at concentrations approx 4- to 5-fold lower than those required for an equivalent inhibition of TAT response; (3) in the presence of cortexolone, deoxycorticosterone, 11 beta-hydroxyprogesterone and dexamethasone-3'-oxetanone, there was a partial agonistic effect (30-50%) on TAT and AAT responses, whereas there was a mainly antagonistic effect (very weak agonistic effect: 0-10%) on GGT response; (4) regardless of the steroid or its full or partial agonist activity, a given TAT induction level (50%, for example) always corresponded to the same AAT and GGT induction levels (50 and 10% respectively). We provide evidence showing that the three above-mentioned biological responses are mediated via the same type of glucocorticoid receptor binding site. Consequently, this differential behavior probably originates from a phenomenon occurring after the common steps (activation, translocation) that follow the formation of the steroid-receptor complex. This leads us to propose a model in which this phenomenon is assumed to originate from a difference in the affinities of the activated receptor for the nuclear acceptor sites of the TAT and GGT genes.
Gagne
D
D
Institut National de la Santé et de la Recherche Médicale, Unité 58, Montpellier, France.
Labhilili
M
M
Pons
M
M
D000410:Alanine Transaminase / Q000096:biosynthesis; D000818:Animals; D002460:Cell Line; D003350:Cortodoxone / Q000494:pharmacology; D003900:Desoxycorticosterone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004790:Enzyme Induction; D004963:Estrenes / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology*; D006908:Hydroxyprogesterones / Q000494:pharmacology; D008114:Liver Neoplasms, Experimental / Q000201:enzymology*; D015735:Mifepristone; D011281:Pregnatrienes / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D011397:Promegestone / Q000494:pharmacology; D014444:Tyrosine Transaminase / Q000096:biosynthesis; D005723:gamma-Glutamyltransferase / Q000096:biosynthesis
D004963:Estrenes; D005938:Glucocorticoids; D006908:Hydroxyprogesterones; D011281:Pregnatrienes; C030228:11-hydroxyprogesterone; D015735:Mifepristone; C029415:deacylcortivazol; D003900:Desoxycorticosterone; D011374:Progesterone; D003907:Dexamethasone; D011397:Promegestone; D005723:gamma-Glutamyltransferase; D000410:Alanine Transaminase; D014444:Tyrosine Transaminase; D003350:Cortodoxone